Public-registry site landscape for NCT07734415, a Atopic Dermatitis study sponsored by Inmagene LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07734415 (registry record) |
| Sponsor | Inmagene LLC |
| Condition(s) | Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema |
| Phase | PHASE2 |
| Listed sites | 23 |
| Site countries | United States, Canada |
At Inmagene Site 1 — one of the facilities listed on this trial — 1 other study is actively recruiting Atopic Dermatitis patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07734415 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →